Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   5/06/2026
195,34 USD (-0,57%)
(-0,57%)   5/06/2026
Grafiek Biogen Inc. Grafiek Biogen Inc.

Biogen Inc. in het nieuws

4 juni 2026 · Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy · Persbericht

4 juni 2026 · EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus · Persbericht

22 mei 2026 · Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky · Persbericht

18 mei 2026 · BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations · Persbericht

16 mei 2026 · Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB) · Persbericht

14 mei 2026 · Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease · Persbericht

8 mei 2026 · Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease · Persbericht

20 april 2026 · Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region · Persbericht

31 maart 2026 · Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology · Persbericht

30 maart 2026 · FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties